Metropolis Healthcare informed BSE and NSE on Monday (October 6) that it recorded a 23% year-on-year consolidated revenue growth for Q2FY26, driven by preventive health check-ups and wellness services.
The update precedes formal financial results, which are pending board approval.
Core Diagnostics moved from breakeven in Q4FY25 to a high single-digit margin in Q2FY26. DAPIC (Dehradun) and Scientific Pathology (Agra) outperformed the company’s average margin.
TruHealth Wellness and Specialty segments grew 25% and 36% year-on-year, respectively. B2C revenues rose 16%, while B2B revenues increased 34%. The company remains debt-free with a net cash surplus of ₹55 crore.
The company also acquired Ambika Pathology Laboratory, Kolhapur, on September 18, to strengthen its presence in Western Maharashtra and set up a mini reference laboratory for surrounding districts.
On a standalone basis, revenue grew 12% year-on-year, supported by higher patient and test volumes, favorable product mix, and improved realisations.
EBITDA margins improved quarter-on-quarter and year-on-year. CNBCTV18